Additional Resources

Note: These Web sites are external to AstraZeneca. AstraZeneca does not possess editorial control of their content and no endorsement, expressed or implied, is intended.

The Allergy & Asthma Network Mothers of Asthmatics is a national nonprofit network of families, founded in 1995, whose desire is to overcome, not cope with, allergies and asthma. The shortest route to that goal is knowledge. That’s why AANMA produces the most accurate, timely, practical, and livable alternatives to suffering.

ARE THERE FAKES AND FRAUDS IN YOUR NEBULIZER?
An article from the Fall 2004 edition of Allergy and Asthma Today discussing what to look for in identifying imitation nebulizer medications.

THE TRUTH ABOUT ILLEGALLY MANUFACTURED NEBULIZER MEDICATIONS
An article from the Winter 2006 edition of Allergy and Asthma Today discussing the dangers associated with pharmacy manufactured products

These materials require Adobe^® Reader^®. You can download the reader for free by clicking here or on the icon below.

Web sites

If you have additional questions regarding compounding and pharmacy manufacturing visit these Web sites:

To report complaints or problems associated with compounded drugs by phone at 1-800-FDA-1088 or online.

For current information about the pharmacy profession visit the American Pharmacists Association.

For additional tools and resources to assist professionals that compound medication visit the American Society of Health-System Pharmacists.

For more information about the practice of compounding of medications, please visit the International Academy of Compounding Pharmacists.

For questions or issues with specific pharmacies in your area, please contact your State Board of Pharmacy.

Find the most up to date information about studies and surveys regarding compounding Click here.

For more supporting information please call the AstraZeneca Information Center at 1-800-236-9933.

NEXT: See the latest news about pharmacy manufacturing

Indication and Important Safety Information

PULMICORT RESPULES is indicated for the maintenance treatment of asthma and as prophylactic therapy in children ages 12 months to 8 years.

PULMICORT RESPULES is not a bronchodilator and is NOT indicated for the relief of acute bronchospasm.

The most common adverse events reported in clinical trials, regardless of relationship to treatment, include respiratory infection, rhinitis, coughing, and otitis media.

Inhaled corticosteroids may cause a reduction in growth velocity. The long-term effect on final adult height is unknown.

PULMICORT RESPULES, like other inhaled corticosteroids, may impact the hypothalamic-pituitary-adrenal axis, especially in susceptible individuals, in young children, and in patients given high doses for prolonged periods.

Adrenal insufficiency may occur when transferring patients from systematic corticosteroids (see WARNING in full Prescribing Information).

Patients taking immunosuppressant doses of corticosteroids should avoid exposure to infections such as chicken pox and measles.

Please see accompanying full Prescribing Information.

This Web site is intended for US Health Care professionals only.

PULMICORT RESPULES is a registered trademark of the AstraZeneca group of companies.